Orthocell has today reached another significant milestone with the successful completion of its Remplir™ 510(k) nerve repair regulatory study, validating Remplir as a safe and effective biological medical device for use in the surgical repair of peripheral nerves.
Read more
Orthocell (ASX:OCC) has announced the commencement of a nerve repair study aimed at supporting product marketing initiatives and international regulatory and reimbursement strategies for its nerve repair device, Remplir.
Read more